CD4 and neoplasm: After 7-day treatment of toripalimab (PD-1 monoclonal antibody, 10 μg/mL) or isotype IgG4 antibody as negative control, we investigated the ratio of CD8+/CD4+ T cells and the effect of tumor killing by fixable viability stain (FVS).